H.C. Wainwright lowered the firm’s price target on Repare Therapeutics (RPTX) to $3 from $5 and keeps a Buy rating on the shares. The firm says the initial RP-1664 data “raises questions over its viability.” As such, the firm removed risk-adjusted revenue forecasts for the agent.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX: